AbbVie’s upadacitinib a small molecule Janus kinase inhibitors (rinvoq) shows promise as maintenance drug for ulcerative colitis

Phase III study showed 49% treated with 15 mg of upadacitinib & 62% treated with 30 mg achieved endoscopic improvement at 52 weeks vs 14% with placebo. Also, 35% on 15 mg upadacitinib and 49% on the 30 mg dose achieved histologic-endoscopic mucosal improvement vs 12% in placebo.

SPS commentary:

Upadacitinib is currently licensed in the UK for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Upadacitinib may be used as monotherapy or in combination with methotrexate.

Biospace Inc.